NIKKEI 225
27,522.26 -250.64 (-0.90%) HANG SENG
24,965.55 +13.25 (+0.05%) CRUDE OIL
85.72 +0.58 (+0.68%) GOLD FUTURES
1,836.10 +4.30 (+0.23%) DOW
34,265.37 -450.03 (-1.30%) BTC-GBP
26,751.37 +785.04 (+3.02%)
Aldeyra Therapeutics, Inc. (ALDX)
After hours:
| Previous close | 3.4700 |
| Open | 3.4200 |
| Bid | 3.2200 x 2200 |
| Ask | 3.3300 x 1800 |
| Day's range | 3.2400 - 3.5200 |
| 52-week range | 3.2400 - 15.9500 |
| Volume | |
| Avg. volume | 1,184,754 |
| Market cap | 188.799M |
| Beta (5Y monthly) | 1.52 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.0840 |
| Earnings date | 09 Mar 2022 - 14 Mar 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 20.40 |
- Business Wire
Aldeyra Therapeutics Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra®
LEXINGTON, Mass., January 11, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company discovering and developing innovative therapies for the treatment of immune-mediated diseases, today announced positive top-line data from a Phase 2 clinical trial comparing ocular discomfort and itching symptom scores of reproxalap ophthalmic solution 0.25% (reproxalap), an investigational new drug, versus Xiidra® (lifitegrast ophthalmic solution 5%) in patients with dry eye disease.
- Business Wire
Aldeyra Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BioConnect Virtual Conference
LEXINGTON, Mass., January 06, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company discovering and developing innovative therapies for the treatment of immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright BioConnect Virtual Conference.
- Business Wire
Aldeyra Therapeutics Completes Enrollment in Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy
LEXINGTON, Mass., January 04, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company discovering and developing innovative therapies for the treatment of immune-mediated diseases, today announced completion of enrollment in Part 1 of the Phase 3 GUARD Trial of ADX-2191 (intravitreal methotrexate 0.8%) in patients with proliferative vitreoretinopathy (PVR), a rare, sight-threatening ocular disease with no approved therapy.
